Nrf2 as a Potential Therapeutic Target for Traumatic Brain Injury
Journal of Integrative Neuroscience · 27.06.2023 · 22 (4)
DOI: 10.31083/j.jin2204081 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Integrative Neuroscience, online erschienen am 27.06.2023. Verfasst von P M Abdul Muneer. Beteiligte Einrichtung: Laboratory of CNS Injury and Molecular Therapy, JFK Neuroscience Institute, Hackensack Meridian JFK University Medical Center, Edison, NJ 08820, USA. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: New Jersey Commission on Brain Injury Research.
Abstract (Originalsprache)
In this review, we discuss the possibility and feasibility of nuclear factor erythroid 2-related factor 2 (Nrf2) as a therapeutic target to minimize the devastating effects of a brain injury. To complete this review, comprehensive literature searches were conducted in MEDLINE, PubMed, Embase, and PsycINFO databases for English scientific peer-reviewed articles through December 2022. This short review addressed the different sources of oxidative stress and its effects on blood-brain barrier (BBB) dysfunction, mitochondrial damage, and changes in a variety of inflammatory molecules associated with central nervous system (CNS) injury. At last, we explained the potential efficacy of the Nrf2 transcription factor in reducing oxidative stress-mediated secondary damages after a CNS injury. The role of CPUY192018, an inhibitor of Nrf2-Keap1 protein-protein interaction in protecting the injured brain cells is given as evidence of Nrf2’s role in activating antioxidant genes. Overall, the scope of Nrf2 in developing therapeutic interventions for a variety of pathophysiological conditions associated with CNS injury-induced free radical/inflammatory signaling is acknowledged. Nrf2 has a widespread application in basic and clinical neuroscience for understanding and treating free radical/inflammatory signaling disorders, including neurological diseases. The development of innovative therapeutic strategies using Nrf2-inducing agents can be applied to reduce the complications of TBI before advancing it to posttraumatic stress disorder (PTSD).
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Laboratory of CNS Injury and Molecular Therapy, JFK Neuroscience Institute, Hackensack Meridian JFK University Medical Center, Edison, NJ 08820, USA.
Förderung
- New Jersey Commission on Brain Injury Research
Zitieren
APA
Muneer, P. M. A. (2023). Nrf2 as a Potential Therapeutic Target for Traumatic Brain Injury. Journal of Integrative Neuroscience, 22(4). https://doi.org/10.31083/j.jin2204081
Vancouver
Muneer PMA. Nrf2 as a Potential Therapeutic Target for Traumatic Brain Injury. Journal of Integrative Neuroscience. 2023;22(4). doi:10.31083/j.jin2204081
BibTeX
@article{Muneer2023,
author = {Muneer, P M Abdul},
title = {Nrf2 as a Potential Therapeutic Target for Traumatic Brain Injury},
journal = {Journal of Integrative Neuroscience},
year = {2023},
volume = {22},
number = {4},
doi = {10.31083/j.jin2204081}
}
EUVIMED